Medicine and Health Sciences Commons^™

Expanding Circle Of Inhibition: Small-Molecule Inhibitors Of Bcl-2 Asanticancer Cell And Antiangiogenic Agents, Benjamin David Zeitlin, Isaac J. Zeitlin, Jacques E. Nör

Benjamin Zeitlin

The specific targeting of diseases, particularly cancer, is a primary aim in drug development, as specificity reduces unwelcome effects on healthy tissue and increases drug efficacy at the target site. Drug specificity can be increased by improving the delivery system or by selecting drugs with affinity for a molecular ligand specific to the disease state. The role of the prosurvival Bcl-2 protein in maintaining the normal balance between apoptosis and cellular survival has been recognized for more than a decade. Bcl-2 is vital during development, much less so in adults. It has also been noted that some cancers evade apoptosis …